The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
What does the Cardiovascular-Kidney-Metabolic (CKM) Syndrome mean for nephrologists?
EuReCa-M Working Group
Speaker
Patrick Mark, United Kingdom
Panellists
Shanmugakumar Chinappa, United Kingdom
Evangelia Ntounousi, Greece
Moderator
Francesca Mallamaci, Italy